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Abstract
The L-type amino acid transporter-1 (LAT1, SLC7A5) is upregulated in a wide range of human cancers, positively
correlated with the biological aggressiveness of tumors, and a promising target for both imaging and therapy.
Radiolabeled amino acids such as O-(2-[18F]fluoroethyl)-L-tyrosine (FET) that are transport substrates for system L
amino acid transporters including LAT1 have met limited success for oncologic imaging outside of the brain, and thus
new strategies are needed for imaging LAT1 in systemic cancers. Here, we describe the development and biological
evaluation of a novel zirconium-89 labeled antibody, [89Zr]DFO-Ab2, targeting the extracellular domain of LAT1 in a
preclinical model of colorectal cancer. This tracer demonstrated specificity for LAT1 in vitro and in vivo with excellent
tumor imaging properties in mice with xenograft tumors. PET imaging studies showed high tumor uptake, with
optimal tumor-to-non target contrast achieved at 7 days post administration. Biodistribution studies demonstrated
tumor uptake of 10.5 ± 1.8 percent injected dose per gram (%ID/g) at 7 days with a tumor to muscle ratio of 13 to 1.
In contrast, the peak tumor uptake of the radiolabeled amino acid [18F]FET was 4.4 ± 0.5 %ID/g at 30 min after
injection with a tumor to muscle ratio of 1.4 to 1. Blocking studies with unlabeled anti-LAT1 antibody demonstrated a
55% reduction of [89Zr]DFO-Ab2 accumulation in the tumor at 7 days. These results are the first report of direct PET
imaging of LAT1 and demonstrate the potential of immunoPET agents for imaging specific amino acid transporters.
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Introduction
Alterations in metabolism and nutrient transport are
hallmarks of neoplastic cells and represent important targets
for molecular imaging. A prototypic example is the Warburg
effect, the upregulation of the conversion of glucose to lactate
via glycolysis, which occurs in many cancers and is the basis of
clinical oncologic positron emission tomography (PET) imaging
with the glucose analogue, 2-deoxy-2-[18F]fluoro-D-glucose
(FDG). Amino acid transport is also increased in many cancers
and has been effectively targeted with radiolabeled amino acid
substrates for PET and single photon emission computed
tomography (SPECT) imaging. The majority of amino acid-
based tracer development has focused on system L amino acid
transport, in particular, the solute carrier (SLC) protein L-type
amino acid transporter-1 (LAT1, SLC7A5) which preferentially
mediates the sodium-independent cellular transport of amino
acids with large neutral amino acid side chains such as leucine,
phenylalanine, methionine, tyrosine, and tryptophan [1-3]. The
functional LAT1 transporter, shown in Figure 1, is a disulfide
linked heterodimeric transmemberane protein comprised of two
subunits: a heavy chain glycoprotein (4Fhc; SLC3A2), and the
non-glycosylated LAT1 light chain protein with 12-
transmembrane domains [4,5]. In addition to providing amino
acids for protein synthesis and other metabolic pathways, LAT1
is involved in promoting cellular growth and proliferation,
angiogenesis, and mTOR pathway signaling [6-8]. Higher
levels of LAT1 are positively correlated with increased
biological aggressiveness and higher mortality in a range of
human cancers including gliomas, breast, lung, prostate, and
ovarian cancers and is thus a promising target for tumor
imaging and therapy [2,9-12].
Radiolabeled L substrates including 6-[18F]fluoro-L-3,4-
dihydroxy-phenylalanine ([18F]FDOPA), L-methyl-11C-
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methionine ([11C]MET), O-(2-[18F]fluoroethyl)-L-tyrosine (FET),
3-[123F]fluoro-α-methyl-L-tyrosine (FAMT), and 3-[123I]iodo-α-
methyl-L-tyrosine (IMT) have been employed extensively for
oncologic imaging in patients; and are particularly effective for
brain tumor imaging as system L transport is up-regulated in
glioma cells and is active at the intact blood-brain barrier
[13-17]. However, these substrates have generally been
inferior to FDG for imaging tumors outside of the brain,
primarily due to lower sensitivity for tumor detection [18]. The
limited sensitivity is a consequence of the bi-directional nature
of LAT1 and other system L transporters, which mediate both
influx and efflux of substrates from cells through an exchange
mechanism of transport. Thus, LAT1 cannot directly
concentrate substrates, leading to relatively low tumor to tissue
ratios. Additionally, the selectivity for radiolabeled amino acids
targeting LAT1 over other system L transporters (LAT2, LAT3
and LAT4) is not typically complete as demonstrated through in
vitro studies using cells with experimentally reduced levels of
LAT1 [19,20]. This lack of selectivity is important because other
system L transporters do not appear to be overexpressed to
the same degree as LAT1 in human cancers [21]. Additionally,
it is not clear if structural modifications of existing system L
transport substrates can substantially improve selectivity for
LAT1 over other system L transporters. Thus, the substrate-
based approach for imaging system L transport has inherent
limitations, and improved PET tracers targeting LAT1 outside of
the brain will require a different strategy.
Towards this end, we have developed an immunoPET
strategy for imaging LAT1 that overcomes many of the
limitations of substrate-based tracers. Monoclonal antibodies
that bind to cell surface targets are versatile and useful
scaffolds for molecular imaging and can achieve high
specificity and binding affinity to tumor antigens of interest. This
work takes advantage of a monoclonal antibody recently
developed by Masuko and colleagues that directly and
specifically target the extracellular domain of native human
LAT-1 protein [1,22,23]. In this report, we describe the
radiolabeling method and the in vitro and in vivo tumor imaging
properties of a novel 89Zr-labeled anti-LAT1 antibody,
[89Zr]DFO-Ab2, in the HCT116 human colorectal cancer model.
Materials and Methods
Production and characterization Anti-human LAT1 mAb
Production and characterization of similar anti-human LAT1
and anti-human CD98 heavy chain (CD98hc) mAb were
reported by Ohno et al [1]. Ab2 was produced against HeLa
cells highly expressing well-defined LAT1 proteins disulfide-
linked to CD98 heavy chain [1]. Female F344/N rats were
administered subcutaneous and intraperitoneal injections (first
and second immunizations) followed by a final intravenous
injection of HeLa cells (3.0 x 107) in each immunization at 3-
week intervals. The immune spleen cells (1.0 x 108) were fused
with X63 mouse myeloma cells (2.5 x 107) using 50%
polyethylene glycol 1540 (Roche, Penzberg, Germany). After
the cell fusion, hybridoma cells were selected in RPMI
supplemented with hypoxanthine, aminopterin and thymidine
Figure 1.  An illustration of the transmembrane L-type amino acid transporter-1 (LAT1) which forms a functional
heterodimer with the 4Fhc heavy chain glycoprotein and is responsible for the transport of amino acids with large neutral
side chains through an exchange mechanism.  
doi: 10.1371/journal.pone.0077476.g001
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(50 x HAT; Invitrogen). Isotypes of the selected anti-human
LAT1 rat mAb (Ab2) used in this study are γ2a and κ. Ab2
strongly reacted with RH7777 rat hepatoma cells (kindly
donated by Dr. Chiba, Mitsubishi Tanabe Pharma, Yokohama,
Japan) expressing human LAT1-GFP and HCT-116 cancer
cells [1,22].
Cell Culture
Rat hepatoma cell line (RH7777) was obtained from
American Type Culture Collection (ATCC; Manassas, VA) and
cultured in Dulbecco's modified Eagle’s medium (DMEM;
Sigma-Aldrich, St. Louis, MO) supplemented with 7% heat-
inactivated fetal bovine serum (FBS; ICN Biomedicals, Aurora,
OH). Human colorectal cancer cell line, HCT-116 (ATCC), was
grown in Iscove’s media supplemented with 10 % FBS and 10
µg/mL gentamicin (Life Technologies, Carlsbad, CA). Cells
were maintained at 37 °C in 5 % CO2, and 90 % humidity. After
4 passages, vials of cells were frozen and stored in liquid
nitrogen for future use. Fresh vials of cells were periodically
thawed and used for in vitro experiments to ensure that
changes to cells did not occur over time or with passages in
culture. For xenograft models, a fresh vial of cells was thawed
10 - 14 days before tumor implantation.
Flow cytometry
For cell-surface staining, cells (3.0 x 105) in 50 µl of PBS
containing 1% BSA were mixed with purified Ab2 (50 µL)
diluted to 10 µg/ml in 1% BSA-PBS and incubated for 1 h at
4°C. Cells were washed three times with PBS, and were
incubated with 50 µl of 1:200 diluted donkey anti-rat IgG (H+L)
antibodies labeled with phycoerythrin (Jackson
ImmunoResearch, West Grove, PA) at 4 °C for 30 min. After
three washes with PBS, cells were suspended in PBS
containing 0.2% BSA, and analyzed with an Accuri C6 flow
cytometer (Tomy Digital Biology, Tokyo, Japan).
Ab2 Antibody and Rat IgG Conjugation and
Radiolabeling
The anti-LAT 1 antibody, Ab2 (1 - 4.5 mg/mL), and control
polyclonal rat IgG from rat serum (Sigma Aldrich, St. Louis,
MO) were conjugated with the chelator desferoxamine (DFO) in
0.1 M sodium carbonate (NaHCO3) buffer (pH 9) following
established methods [24-27]. A 5 mg/ml stock solution of p-
isothiocynatobenzyl-desferroxamine (DFO-Bz-NCS) was made
in DMSO. To each antibody, an 8 fold molar excess of the DFO
chelator, and 0.1 M NaHCO3 buffer was added to bring the
reaction volume to 150 µL and ensure the reaction pH was
maintained at 9. The reaction solution was incubated at 37 °C
for 1 h, and unreacted DFO was removed by size exclusion
chromatography on a 40 kDa cutoff ZebaTM spin desalting
column (Thermo Fisher Scientific, Rockford, IL). The protein
concentration of the resultant DFO functionalized antibodies
were determined by bicinchoninic acid (BCA) assay (Thermo
Scientific, Rockford, IL). 89Zr was produced via the 89Y(p,n)89Zr
reaction on a CS-15 cyclotron (Cyclotron Corporation,
Berkeley, CA) at the Washington University in St. Louis
Cyclotron Facility and purified as previously reported [28]. For
radiolabeling, 18 - 111 MBq (0.5 - 3 mCi) of 89Zr-oxalate
solution (pH ≤ 1) was neutralized to pH 6.9 - 7.2 by first adding
an equivalent volume of 0.2 M HEPES (pH 7), followed by slow
addition of 2M Na2CO3. The DFO functionalized mAb was
added to 89Zr-oxalate solution and incubated at 37 °C for 1 hour
while shaking. A 5 µL aliquot was removed and challenged with
5 µL of 50 mM diethylenetriaminepentaacetic acid (DTPA) to
assay for unreacted and non-specifically bound 89Zr.
Radiochemical purity was determined by ITLC using 50 mM
DTPA as the mobile phase. Antibodies with radiochemical
purity of ≥ 95 % were used without further purification.
Synthesis of [18F]FET
The production of [18F]FET was performed using the Eckert
and Ziegler Modular Lab based on a previously reported
automated procedure with a solid-phase extraction purification
[29]. [18F]fluoride was produced from [18O]H2O via the
18O(p,n)18F reaction on the RDS 111 cyclotron (Siemens, TN).
[18F]FET was formulated in 10 % ethanol in saline for studies.
The specific activity was calculated to be greater than 37 GBq
(1 Ci) per µmol (n=4).
Immunoreactivity Assay
The immunoreactive fraction of [89Zr]DFO-Ab2 was
determined using a modification of the radioactive cellular-
binding assay described by Lindmo et al.[30]. Briefly, HCT116
cells were suspended in microcentrifuge tubes at
concentrations of 3, 2.4, 1.8, 1.5, 1.2, 0.9, 0.6, and 0.3 x 106
cells/mL in 500 µL PBS (pH 7.4). Aliquots of [89Zr]DFO-Ab2
( 50 µL of a stock solution of 0.11 MBq (3 µCi) in 30 mL of 1 %
bovine serum albumin (BSA); 2,000 cpm (1.3 ng) of
radiolabeled mAb were added to each tube (n = 3) for a final
volume of 550 µL. Samples were incubated at room
temperature for 1 h while shaking. After incubation, cells were
pelleted by centrifugation, resuspended and washed twice with
ice-cold PBS. The supernatant was removed and cell
associated activity counted on a γ–counter. The background
corrected count data was compared with the total activity
added. The (total/bound) activity was plotted against the
inverse cell concentration (1/[normalized cell concentration]).
The immunoreactive fraction was determined by linear
regression analysis of the plot, and calculated from the inverse
of the y-intercept.
In vitro Studies
Saturation receptor-binding assay.  The dissociation
constant (Kd) for [89Zr]DFO-Ab2 was measured using a
radioligand saturation receptor-binding assay. Approximately 1
x 105 of LAT-1 expressing HCT116 cells were seeded in a 48
well plate and allowed 48 hours to achieve ~50 % confluency.
The adherent cells were incubated with increasing
concentrations of [89Zr]DFO-Ab2 (0 - 450 nmol/L) in media
containing 10 % FBS to eliminate non-specific binding, at a
total volume of 100 µL for 2 hours at 37 °C. Unbound
radioactivity was removed and the cells washed three times
with phosphate-buffered saline (PBS), pH 7.4. Cells were
removed by trypsinization and cell associated radiation counted
on a γ–counter. The Kd was calculated by fitting a plot of cell-
bound [89Zr]DFO-Ab2 (nmol) vs. the concentration of unbound
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radioligand (nmol/L) to a one-site saturation binding model
using Prism® Ver. 5.0 software (GraphPad Software, San
Diego, CA, USA). This model assumes that the amount of
nonspecific binding is proportional to the concentration of
radioligand.
Rate of Internalization.  HCT116 cells were seeded in 24
well plates at 2.4 x 105 cells per well and were allowed 24 h to
adhere. Fresh complete media was added and cells incubated
with 6 µg/mL of [89Zr]DFO-Ab2 (2 µL of mAb in 200 µL of
complete media) for varying time points: 0.2, 0.5, 1, 2, 4, 6, and
24 h at 37 °C. The media was removed and cells were washed
twice with ice-cold PBS to remove unbound [89Zr]DFO-Ab2.
Thereafter, cells were trypsinized, and treated with 300 µL of
0.1 M sodium citrate (pH 2) at 37 °C for 5 min. After incubation,
cells were pelleted by centrifugation, the amount of cell
surface-bound activity, and intracellular radioactivity was
determined by measuring the radioactivity of the supernatants
and the cell pellets, respectively, in a γ-counter. The relative
percent bound activity for surface bound and internalized
activity was plotted over time.
HCT116 Xenograft Model
All animal experiments were performed according to the
guidelines of the Institutional Animal Care and Use Committee
(IACUC) and the Washington University Animal Studies
Committee specifically approved this study. Animals were
provided food and water ad libitum prior to imaging studies.
Athymic nude nu/nu 7 week old male mice were purchased
from National Cancer Institute (Frederick, MD) and housed
under pathogen-free conditions in an approved facility. Animals
(24-28 g) were implanted subcutaneously (shoulder) with 2.0 x
106 cells of HCT116 cells suspended in 100 µl of saline, and
developed tumors averaging 150-200 mm3 approximately 14
days after implantation.
Biodistribution Studies
Biodistribution studies were conducted to evaluate the
uptake of [89Zr]DFO-Ab2 in HCT116 tumor bearing mice. Mice
were randomized (n = 3 for each group) and warmed gently
under a heat lamp for approximately 5 minutes prior to tail vein
administration of radiotracer. Mice received [89Zr]DFO-Ab2 (3.1
- 3.3 MBq [83 - 88 µCi], 15 - 16 µg of mAb) or [89Zr]DFO-IgG
(1.0 - 2.3 MBq [28 - 57 µCi], 21 - 48 µg of Ab) as a non-specific
control, in 100 µL 0.9 % sterile saline. Animals were euthanized
by cervical dislocation at 3 or 7 days post administration. A
separate set of animals ( n = 4- 5) were injected with 1.8 - 5.6
MBq (50-150 µCi) of [18F]FET in 100 µL of 10% ethanol in
normal saline via tail vein administration, and were sacrificed at
5, 30, and 60 minutes post administration. Organs of interest
(including the tumor) were harvested and weighed, and
radioactivity measured on a gamma-counter. Syringes of the
formulation injected into the animals were used as standards.
Data were background- and decay-corrected, and the percent
injected dose per gram (%ID/g) for each tissue sample
calculated by normalization to the total activity injected.
Blocking studies were performed to investigate the specificity
of [89Zr]DFO-Ab2 for LAT1 in vivo. Non-radiolabeled Ab2
antibody (0.8 mg/mouse) was pre-administered intravenously
(tail vein) 1 hour prior to [89Zr]DFO-Ab2 injection and
biodistribution studies were conducted as described above.
Small-Animal ImmunoPET Imaging
Mice were anaesthetized with 1-2 % isoflurane, injected
intravenously with 3.1 - 3.3 MBq (88 - 98 µCi, 22-25 µg) of
[89Zr]DFO-Ab2 ( n = 3) and imaged on an Inveon small animal
PET/CT scanner (Siemens Medical Solutions) at 72 and 168 h
post injection. Static images were collected for 30 minutes for
the 89Zr PET imaging studies. A separate set of rodents (n= 4)
received 150 µCi of [18F]FET intravenously followed by 60
minute dynamic PET scans. Images were reconstructed with
the Maximum A Posteriory Probability (MAP) algorithm
followed by co-registration with the Inveon Research
Workstation image display software (Siemens Medical
Solutions, Knoxville, TN). Regions of interest (ROI) were
selected from PET images using CT anatomical guidelines and
the associated activity measured with Inveon Research
Workstation software. Maximum Standard uptake values (SUV)
were determined as Bq/cc x animal weight (g)/ injected dose
(Bq).
Immunohistochemistry
Excised tumor masses were fixed in 4 % PFA in PBS and
5-7 µm sections were used for immunostaining. Deparaffined
sections were heated at 60 °C for 20 min and hydrated in
xylene and graded alcohol. Tissue sections were then coated
with normal blocking serum (1:50) for 30 min to reduce
nonspecific binding. Tissue sections were incubated with a
commercially available anti-human LAT1 mAb at 1:100
(TransGenic Inc., Chuo-ku, Kobe) overnight followed by
washing with tris-buffered saline with tween (TBST). Slides
were incubated with biotinylated rabbit anti-rat IgG (Vector
Laboratories, Bulingame, CA) diluted to 1:200 in PBS for 30
min. After three washes with TBST, samples were treated with
ABC reagent (Vector Laboratories) at 1:100 for 30 min. Tissues
were stained with alkaline phosphatase substrate kit (Vector
Laboratories) for 2 min, and then color development was
stopped by placing slides in water. Counterstaining was
conducted with nuclear fast red for 30 min, followed by
dehydration in ethanol. The location of antibody-defined
components were observed under a Zeiss Axiophot
microscope (Zeiss, Thornwood, NY) and photographed.
Statistical Analysis
Data were analyzed with the student t test when comparing
two groups or one way ANOVA with Bonferroni post-test
analysis for multiple comparisons. Differences with 95 %
confidence level (P < 0.05) were considered to be statistically
significant.
Results
Conjugation and Radiolabeling
The anti-LAT1 antibody, Ab2, was modified with the acyclic
bifunctional chelator, Df-Bz-NCS at an 8:1 molar excess of
chelate to protein in sodium carbonate buffer (pH 9). Unreacted
Imaging LAT1 with Zr-89 ImmunoPET
PLOS ONE | www.plosone.org 4 October 2013 | Volume 8 | Issue 10 | e77476
Df-Bz-NCS was removed by size exclusion chromatography,
and the concentration of functionalized anti-LAT1 antibody
quantified by BCA assay. Using this method, we achieved ≥ 90
% recovery of our antibodies; for DFO-Ab2 the post purification
concentration was 4.2 mg/mL and 2.5 mg/mL for non-specific
IgG. Post modification analysis on fast protein liquid
chromatography (FPLC) revealed the antibody maintained its’
integrity with less than 5 % aggregation products observed.
The DFO functionalized antibodies were radiolabeled using
89Zr-oxalate. [89Zr]DFO-Ab2 was radiolabeled at a specific
activity of 5 mCi/mg and the control IgG was radiolabeled at 1
mCi/mg. Under these conditions ≥ 95% of the added activity
was associated with the antibody as determined by radioTLC.
The challenge radiochemical purity as assessed by DTPA
challenge was 97.6 ± 1.2 %, and the radiolabeled mAb was
used without further purification. The resulting specific activities
were 189.1 ± 10 MBq/mg (5.14 ± 0.33 mCi/mg) for [89Zr]DFO-
Ab2, and 48.8 ± 8.1 MBq/mg (1.32 ± 0.22 mCi/mg) for
[89Zr]DFO-IgG.
In Vitro characterization
Flow cytometry studies using rat liver RH7777 cells
transfected with green fluorescent protein (GFP) fused human
and mouse CD98 light chains demonstrated the specificity of
the anti-LAT antibody, Ab2, for human LAT1 (shown in Figure
S1). Interspecies cross reactivity was not observed,
additionally, the antibody did not react with the anchoring CD98
heavy chain. [89Zr]DFO-Ab2 demonstrated saturable binding to
LAT1-expressing HCT116 cells. The concentration at which
[89Zr]DFO-Ab2 occupies 50 % of cell surface receptors (Kd) was
determined to be 112.5 ± 27.2 nM, (shown in Figure 2). To
ascertain the purity and biological integrity of the
radioconjugate, an immunoreactivity assay was conducted and
the immunoreactive fraction at infinite LAT1 antigen excess
was calculated as 0.79 ± 0.11. We examined the binding
kinetics of [89Zr]DFO-Ab2 where surface bound [89Zr]DFO-Ab2
was internalized at 37 °C for various intervals up to 24 h as
shown in Figure 2 [31]. Over-time, the surface-bound activity
decreased as the internalized fraction increased. The
intracellular radioactivity reached a steady-state after 4 hours,
with no change in associated activity between 6 and 21 hours
with approximately 40% of the activity internalized and 60%
bound to the cell surface.
Biodistribution Studies and In Vivo Imaging
We investigated the tumor and normal tissue distribution of
[89Zr]DFO-Ab2 in a subcutaneous model of human colorectal
cancer through PET and biodistribution studies conducted at 3
and 7 days after intravenous administration. Small animal
PET/CT images revealed relatively high accumulation of
activity in the tumor at 3 days post injection (p.i.), although
blood pool, liver, and kidney activity was also relatively high at
this time point. At 7 days p.i., the activity in the tumor persisted
while the non-target tissue activity cleared substantially.
Quantitative region-of-interest analysis of PET images revealed
a 3-fold increase in tumor associated standard uptake values
(SUVs), with values of 2.2 ± 0.07 observed at 3 d increasing to
3.0 ± 0.24 at 7 days (Figure 3). Immunohistochemistry staining
was conducted on the excised tumor mass, and the presence
of LAT1 protein was independently confirmed using a
commercially available anti human LAT1 monoclonal antibody
(Figure 3C).
Figure 2.  In vitro experiments in LAT-1 expressing
HCT-116 cell line.  (A) Receptor saturation using varying
concentrations of the radiolabeled antibody, [89Zr]DFO-Ab2. (B)
Immunoreactivity assay plot of the (total/bound) activity versus
(1/[normalized cell concentration]) of [89Zr]DFO-Ab2,
immunoreactive fraction determined by extrapolation to infinite
antigen excess (1/y-intercept). (C) Surface bound and
internalized cellular accumulation of the radioimmunoconjugate
over time (up to 24 h).
doi: 10.1371/journal.pone.0077476.g002
Figure 3.  In vivo immuno-PET images of [89Zr]DFO-Ab2 in
HCT-116 bearing xenografts.  (A) Representative maximum
intensity projections (MIP) of small animal PET/CT images at 3
and 7 days, where tumor is clearly visualized at 3 d. The tracer
uptake was blocked with 800 µg of excess Ab2-LAT-1 (7 d
block). (B) Maximum standard uptake values confirming
increased tracer accumulation in tumor lesion over time;
significant decrease in accumulation was observed in the
presence of blocking dose. (C) Immunohistochemistry showing
expression of LAT-1 in excised HCT-116 tumor used in this
study.
doi: 10.1371/journal.pone.0077476.g003
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Ex vivo biodistribution studies corroborated the PET data
with high levels of tumor uptake observed for the [89Zr]DFO-
Ab2 immunoPET tracer. The probe was retained in the tumor
with uptake of 9.3 ± 0.84 and 10.5 ± 1.8 %ID/g at 3 and 7 d p.i.,
respectively. Improved contrast was achieved at later time
points, when the blood-pool activity decreased from 5.6 ± 0.36
at 3 d to 3.0 ± 0.07 %ID/g at 7 d p.i. The %ID/g values for most
normal tissues were substantially lower than the tumor at both
time points with clearance of activity from 3 to 7 d (Table 1), a
profile that is consistent with the blood clearance of
radiolabeled antibodies [27,32]. The highest concentration of
activity in normal tissues occurred in the liver with 7.6 ± 1.2 and
7.6 ± 0.36 %ID/g at day 3 and day 7 p.i. respectively, a
distribution typical of radiolabeled antibodies. Accumulation of
activity in bone may be indicative of decomplexation of 89Zr
from the intact functionalized mAb; however the increase from
3.0 ± 0.30 to 3.9 ± 0.25 %ID/g (p = 0.0176) at 3 and 7 d
respectively may be a consequence of tracer metabolism and
localization of 89Zr species into the bone [33,34].
Blocking studies with pre-injection of 0.8 mg of unlabeled
Ab2 were conducted in another group of mice to assess for
specific binding of [89Zr]DFO-Ab2 in vivo. In this group, the
tumor was poorly visualized with tumor associated activity
decreasing to 4.7 ± 0.08 %ID/g at 7 d, a 55% decrease relative
to the control group (p = 0.014). These experiments are in
agreement with the in vitro data and support the specificity of
[89Zr]DFO-Ab2 for LAT1. As an additional control,
biodistribution studies were performed using 89Zr-labeled non-
targeted polyclonal rat IgG ([89Zr]DFO-IgG) to assess the
contribution of non-specific uptake mechanisms such as blood
volume and passive diffusion. We observed superior tumor
accumulation with [89Zr]DFO-Ab2 compared to [89Zr]DFO-IgG
with tumor uptake of 1.5 ± 0.42 %ID/g (p = 0.0006) at 7 days
p.i. These results further support the specificity of [89Zr]DFO-
Ab2 for LAT1 in vivo.
To further assess the performance of [89Zr]DFO-Ab2, we
compared the biodistribution and PET imaging properties of
[89Zr]DFO-Ab2 with the well-established system L substrate,
[18F]FET, in the same HCT116 tumor model. The peak uptake
of [18F]FET occurred at 30 min p.i. with 4.4 ± 0.51 %ID/g in the
tumor as shown in Table 2. The absolute amount of tumor
uptake observed with [18F]FET as well as the tumor to normal
tissue ratios were significantly lower than those observed with
[89Zr]DFO-Ab2 as illustrated in Figure 4. These results with
[18F]FET are in keeping with previous reports in preclinical and
human tumor imaging studies for neoplasms outside of the
brain [18].
Discussion
The system L transporter, LAT1, is an emerging biomarker
for tumor aggressiveness and prognosis. Additionally, this
amino acid transporter is being explored for targeted delivery of
therapeutic agents. To date approaches to non-invasively
image LAT1 transporter levels in malignant tissue have
focused on radiolabeled amino acids that are transport
substrates for LAT1. However, these substrates have limited
utility outside of the brain due to relatively low sensitivity for
tumor. This limitation led us to develop an immunoPET agent
targeting amino acid transporters. The novel 89Zr-labeled anti-
LAT mAb, [89Zr]DFO-Ab2, demonstrates high affinity and
specificity for human LAT1 in vitro and in vivo. Flow cytometry
data using Ab2 shows no cross-reactivity with other
heterodimeric amino acid transporters including the system L
Table 1. Biodistribution of intravenously administered 89Zr-Ab2-DFO in selected organs of male Athymic nu/nu mice bearing
subcutaneous HCT-116 tumors.
 [89Zr]DFO-Ab2 Block Rat IgG
Organ 3 d (n=3) 7 d (n = 3) 7 d (n = 3) 3 d (n=3) 7 d (n=3)
blood 5.58 +/- 0.36 3.04 +/- 0.07 3.45 +/- 0.35 4.76 +/- 0.39 3.20 +/- 0.63
lung 3.32 +/- 0.24 2.25 +/- 0.12 2.59 +/- 0.62 2.28 +/- 0.26 2.83 +/- 1.15
liver(all) 7.64 +/- 1.24 7.63 +/- 0.36 8.56 +/- 0.82 9.77 +/- 1.30 10.38 +/- 2.15
spleen 4.26 +/- 0.48 3.88 +/- 0.15 4.73 +/- 0.78 3.56 +/- 1.20 4.85 +/- 1.20
kidney 11.15 +/- 1.70 6.99 +/- 1.04 7.33 +/- 0.20 2.63 +/- 0.31 2.28 +/- 0.15
muscle 1.14 +/- 0.11 0.81 +/- 0.05 0.88 +/- 0.06 0.61 +/- 0.07 0.55 +/- 0.11
heart 2.59 +/- 0.10 1.68 +/- 0.15 1.79 +/- 0.09 1.57 +/- 0.26 1.23 +/- 0.07
brain 0.25 +/- 0.04 0.14 +/- 0.03 0.16 +/- 0.03 0.18 +/- 0.05 0.14 +/- 0.03
bone 2.99 +/- 0.30 3.86 +/- 0.25 4.39 +/- 0.38 1.99 +/- 0.49 3.01 +/- 0.97
testes 2.16 +/- 0.16 1.95 +/- 0.06 2.01 +/- 0.12 1.05 +/- 0.20 0.88 +/- 0.12
pancreas 1.17 +/- 0.12 1.10 +/- 0.08 0.95 +/- 0.03 0.78 +/- 0.24 0.78 +/- 0.14
tumor 9.29 +/- 0.84 10.49 +/- 1.78 4.70 +/- 0.08 2.24 +/- 0.47 1.49 +/- 0.42
stomach 0.40 +/- 0.09 0.26 +/- 0.06 0.32 +/- 0.09 0.43 +/- 0.10 0.27 +/- 0.05
sm int 0.78 +/- 0.05 0.55 +/- 0.10 0.63 +/- 0.05 0.60 +/- 0.04 0.52 +/- 0.09
u lg int 0.80 +/- 0.22 0.51 +/- 0.08 0.57 +/- 0.14 0.57 +/- 0.10 0.51 +/- 0.13
l lg int 0.67 +/- 0.12 0.53 +/- 0.06 0.57 +/- 0.09 0.58 +/- 0.14 0.39 +/- 0.09
Data expressed in %ID/g ± SD.             
doi: 10.1371/journal.pone.0077476.t001
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transporter LAT2 (see Figure S1). Incorporation of metal
chelator, DFO, does not significantly affect the
immunoreactivity and provides a means for high labeling
efficiency with 89Zr which has physical half-life (3.3 days)
compatible with the pharmacokinetics of intact mAbs.
Biodistribution and small animal PET/CT studies with
[89Zr]DFO-Ab2 show in vivo binding to LAT1 in the HCT116
colorectal cancer model, a cell line that is known to express
LAT1 in high abundance [22]. Tumor uptake of the tracer was
high and persistent with tumor associated activity of 9.3 ± 0.84
Table 2. Ex vivo biodistribution of [18F]FET after intravenous
injection in athymic nu/nu male mice HCT116 xenografts.
Organs 5 min (n=5) 30 min (n=4) 60 min (n=4)
blood 3.89 +/- 0.41 4.13 +/- 0.25 4.20 +/- 0.71
lung 3.41 +/- 0.49 3.45 +/- 0.19 3.90 +/- 0.60
liver(all) 3.17 +/- 0.43 3.11 +/- 0.19 3.69 +/- 0.67
spleen 3.39 +/- 0.66 3.18 +/- 0.18 3.07 +/- 0.59
kidney 3.57 +/- 0.46 3.17 +/- 0.22 4.38 +/- 0.47
muscle 2.95 +/- 0.64 3.17 +/- 0.31 3.46 +/- 0.59
heart 3.25 +/- 0.66 3.60 +/- 0.14 3.72 +/- 0.63
brain 2.38 +/- 0.34 2.64 +/- 0.14 2.63 +/- 0.39
bone 1.52 +/- 0.24 2.14 +/- 0.30 1.55 +/- 0.25
testes 2.13 +/- 0.45 2.37 +/- 0.23 2.73 +/- 0.51
pancreas 9.83 +/- 2.86 11.52 +/- 2.26 11.29 +/- 2.50
tumor 2.75 +/- 0.69 4.38 +/- 0.51 3.17 +/- 0.72
stomach 2.69 +/- 0.93 2.37 +/- 0.35 2.88 +/- 1.48
sm int 3.26 +/- 0.54 3.48 +/- 0.19 3.81 +/- 0.76
u lg int 2.85 +/- 0.48 3.00 +/- 0.18 3.33 +/- 0.49
l lg int 2.23 +/- 0.29 4.59 +/- 0.39 2.75 +/- 0.45
Data expressed in %ID/g ± SD       
doi: 10.1371/journal.pone.0077476.t002
Figure 4.  Tumor-to-organ ratios of the immunoPET
tracer, [89Zr]DFO-Ab2 without (blue) and with blocking
doses (green) of unlabeled Ab2 at 7 days post injection
with comparison to the 18F-labeled amino acid, [18F]FET, at
30 minutes after intravenous administration.  
doi: 10.1371/journal.pone.0077476.g004
and 10.5 ± 1.8 %ID/g at 3 and 7 d p.i., respectively. Excellent
tumor-to-non-target organ contrast was achieved at 7 days with
tumor-to-blood and tumor-to-muscle ratios of 3.5:1 and 13:1
respectively compared to 1.1:1 and 1.4:1 for the system L
transport substrate, [18F]FET, at 30 minutes. The results
strongly suggest the superiority of immunoPET targeting LAT1
over system L transport substrates like [18F]FET for neoplasms
located outside of the brain. A number of radiolabeled amino
acids targeting system L transport including [123I]IMT ,
[18F]FDOPA, and [18F]FAMT have been evaluated in humans
for oncologic imaging. The presence of an α-methyl group
increases the selectivity of aromatic amino acids for LAT1 over
other system L transporters, and tracers like IMT and FAMT
may show somewhat higher tumor to background ratios
compared to FET [17]. However, the exchange mechanism of
LAT1 transport limits the tumor to background ratios that can
be achieved with substrate-based imaging agents.
While the [89Zr]DFO-Ab2 has superior contrast in all organs
compared to [18F]FET, the low normal tissue uptake of
[89Zr]DFO-Ab2 in mice may be due in part to lack of recognition
of mouse LAT1 by this mAb (Figure S1). Ab2 is an anti-human
LAT1 antibody with no cross species reactivity, and thus LAT1
binding in normal mouse tissues does not occur, as confirmed
by the blocking study where all organ distribution with
exception of the tumor were similar (see Table 1). The lack of
binding to LAT1 in normal tissues may artificially increase the
tumor to tissue ratios observed in these studies. In vivo
characterization of amino acid transporter substrates are also
limited as the relative transport rates of [18F]FET by human
LAT1 versus its mouse homologue have not yet been
measured. The species differences may contribute to the
differences in [18F]FET uptake by human tumor xenografts and
normal mouse tissues, however, [18F]FET has been
successfully used to image tumors derived from mouse and rat
cell lines, indicating this tracer is recognized by rodent system
L transporters [35-37]. LAT1 is regarded as an oncofetal
protein and its’ expression is limited in normal adult tissue,
thus, the uptake of [89Zr]DFO-Ab2 in most human tissues and
organs may be relatively low as in this mouse model. The high
liver uptake of [89Zr]DFO-Ab2 is possibly a result of the
biological clearance of the tracer, and is a profile typical of
radiolabeled antibodies. However, colorectal carcinoma
frequently metastasizes to the liver, and the low tumor to liver
contrast of 1.1:1 may limit the utility of the [89Zr]DFO-Ab2 for
detecting lesions in the liver. Despite the potential limitations,
our results collectively show immunoPET has potential
advantages including higher specificity for LAT1 and improved
tumor visualization compared to the traditional substrate-based
approach. The reported immunoPET agent, [89Zr]DFO-Ab2, is
the first example of a macromolecule against LAT1. Other
constructs such as affibodies or minibodies may also be
advantageous techniques for directly probing expression of
LAT1. Currently, these approaches have yet to be explored;
however, the availability of effective non-substrate tracers for
imaging LAT1 would enable detailed investigations into the
relative importance of LAT1 protein levels versus substrate flux
in tumor biology.
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A potential confound when evaluating large-molecule probes
like antibodies is enhanced permeability and retention (EPR)
effect due to the leaky vasculature characteristic of solid
tumors. To confirm that the accumulation of [89Zr]DFO-Ab2 in
tumor tissue was due to specific binding rather than non-
specific mechanisms, control experiments using non-specific
polyclonal 89Zr-labeled IgG and a blocking study using excess
unlabeled Ab2 were employed. We observed 5-fold higher
tumor uptake with [89Zr]DFO-Ab2 compared to non-specific rat
IgG and a 55 % decrease in tumor associated activity with
preinjection of a 50-fold excess by weight of unmodified
antibody. Together with the in vitro data, these experiments
indicate that [89Zr]DFO-Ab2 binds specifically to LAT1 in vivo.
Radiolabeled amino acids such as [18F]FET have been most
successfully utilized clinically for brain tumors but have been
less effective for extracranial malignancies. System L is active
at the blood-brain barrier (BBB) which allows transport
substrates to reach the entire brain tumor volume including
non-contrast enhancing regions on magnetic resonance
imaging (MRI) without disrupted BBB. Additional studies will be
needed to assess the utility of [89Zr]DFO-Ab2 for imaging brain
tumors that do not exhibit contrast enhancement due to intact
BBB. It is possible that LAT1 upregulation in the endothelium of
non-enhancing gliomas could serve as an imaging target for
[89Zr]DFO-Ab2 and related compounds. Alternatively, receptor-
mediated transcytosis approaches that exploit the transferrin
and insulin-like growth factor receptors for targeted delivery of
large antibodies and nanoparticles in mouse, rat, and Rhesus
monkey models could be used [38-41]. Further work will be
needed to elucidate the role of immunoPET targeting LAT1 in
brain tumors that do not exhibit contrast enhancement due to
intact BBB.
In conclusion, we have developed an immunoPET agent
targeting human LAT1 that demonstrates specific in vivo
binding in a mouse model of colorectal cancer with excellent
tumor visualization. To our knowledge, these results are the
first reported example of a PET imaging agent that directly
binds to a specific amino acid transporter. Given the
importance of LAT1 in human cancer, the ability to directly
visualize and quantify LAT1 transporter density has potential
utility as a new tool for oncologic imaging. This imaging
strategy also has the potential to substantially extend amino
acid transporter-based oncologic imaging to a wide range of
neoplasms not effectively imaged with currently available
radiolabeled amino acids.
Supporting Information
Figure S1.  Ab2 reactivity with LAT1 in RH7777 cells
transfected with cDNA of green fluorescent protein (GFP)
fused human CD98hc or various human CD98lcs.
(TIF)
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